TSHA Stock Forecast & Price Target

Taysha Gene Therapies is viewed positively because TSHA-102 is showing unusually strong efficacy in Rett syndrome, with an 83% response rate at six months that improved to 100% at 12 months in 12 patients, alongside 310 total functional gains and 31 developmental milestones, all well above the FDA’s 33% bar. The thesis is further strengthened by a clean safety profile across N=29 treated patients, with no treatment-related serious adverse events or dose-limiting toxicities, which supports confidence in the AAV9-based CNS platform and the reproducibility of the signal. The company also benefits from trial-design credibility, including blinded assessment and rigorous endpoint capture, while the fully enrolled 17-patient pivotal study and 1H27 interim data create a clear path to de-risking the program further.

Taysha Gene Therapies is viewed negatively because its lead program TSHA-102 remains exposed to substantial clinical uncertainty, and AAV-based gene therapies have a record of severe immunological responses and DRG toxicity that could undermine efficacy and safety. Regulatory risk is also elevated since none of its drugs have been approved by FDA or EMA, intrathecal gene therapy has no approved precedent, and approval delays could materially hurt the share price. Financially, the company is likely to need additional equity financing to fund development and build a commercial presence, creating dilution risk, while competition from better-resourced biotech and pharma peers is intense.